NCT01892046View on ClinicalTrials.gov

Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

February 28, 2017

Study Completion Date

July 31, 2017

Conditions
Cancer
Interventions
DRUG

SNX-5422

Capsule dosed every other day for 21 days out of a 28 day cycle. Dose escalation based on safety. Maintenance doses at the maximum tolerated dose.

Trial Locations (4)

10065

Memorial Sloan Kettering Cancer Center, New York

20007

Georgetown University Medical Center, Washington D.C.

30912

Georgia Regents University Cancer Center, Augusta

07601

Hackensack University Medical Center, Hackensack

All Listed Sponsors
lead

Esanex Inc.

INDUSTRY

NCT01892046 - Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors | Biotech Hunter | Biotech Hunter